Recruiting Clinical Trials

Displaying 1 - 10 of 227 result(s)
Study Title Condition Phase Location
A Phase I, Open-label, Multi-center Study of PIT565 in Patients With Relapsed and/or Refractory B-cell Malignancies B-cell Non-Hodgkin Lymphoma (B-NHL), B-cell Acute Lymphoblastic Leukemia (B-ALL) Phase 1
  • Country: 
    France
  • Country: 
    Israel
  • Country: 
    Italy
  • Country: 
A Phase II, Multicenter, Two-cohort Study of Oral MET Inhibitor Capmatinib in Chinese Adult Patients With EGFR Wild-type (wt), ALK Rearrangement Negative, MET Exon 14 Skipping Mutations, Advanced Non-small Cell Lung Cancer (NSCLC) Who Are Treatment N ... Non-Small Cell Lung Cancer (NSCLC) Phase 2
  • Country: 
    China
A Randomized, Multi-centric, Placebo-controlled, Participant and Investigator-blinded Study to Evaluate the Safety, Tolerability and Efficacy of TIN816 in Adult Patients at Risk for Acute Kidney Injury Following Cardiac Surgery. Acute Kidney Injury Following Cardiac Surgery Phase 2
  • Country: 
    France
An Open-label, Multi-center, Global, Rollover Study for Patients Who Have Previously Been Treated With Capmatinib (INC280) as Monotherapy or in Combination in a Novartis Sponsored Trial. Advanced Solid Tumors Which Are cMET-dependent Phase 2
  • Country: 
    United States
  • Country: 
    Belgium
  • Country: 
    Canada
  • Country: 
An Open Label, Multi-center Asciminib Roll-over Study to Assess Long-term Safety in Patients Who Have Completed a Novartis Sponsored Asciminib Study and Are Judged by the Investigator to Benefit From Continued Treatment Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive Phase 3
  • Country: 
    United States
  • Country: 
    Argentina
  • Country: 
    Brazil
  • Country: 
A Phase 3b, Multi-center, Open-label, Treatment Optimization Study of Oral Asciminib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Previously Treated With 2 or More Tyrosine Kinase Inhibitors. Chronic Myelogenous Leukemia Phase 3
  • Country: 
    Argentina
  • Country: 
    Austria
  • Country: 
    Brazil
  • Country: 
An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood, Anaplastic Oligodendroglioma, Glioblastoma, Pilocytic Astrocytoma, Giant Cell Astrocytoma, Pleomorphic Xanthoastrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Angiocentric Glioma, Chordoid Glioma of Third Ventricle, Gangliocytoma, Ganglioglioma, Anaplastic Ganglioglioma, Dysplastic Gangliocytoma of Cerebrellum, Desmoplastic Infantile Astrocytoma and Ganglioglioma, Papillary Glioneuronal Tumor, Rosette-forming Glioneurona Tumor, Central Neurocytoma, Extraventricular Neurocytoma, Cerebellar Liponeurocytoma, Neurofibromatosis Type 1 Phase 4
  • Country: 
    United States
  • Country: 
    Belgium
  • Country: 
    Canada
  • Country: 
A Phase II Open-label, 2-Part, Multi-center Study of BYL719 (Alpelisib) in Combination With Fulvestrant for Men and Postmenopausal Women With PIK3CA Mutation Hormone Receptor (HR) Positive, HER2-negative, Advanced Breast Cancer Which Progressed on or ... Advanced Breast Cancer Phase 2
  • Country: 
    Japan
A Randomized, Double-blind, Phase III Study, Comparing NIS793 in Combination With Gemcitabine and Nab-paclitaxel Versus (vs.) Placebo Combined With Gemcitabine and Nab-paclitaxel for First Line Treatment of Metastatic Pancreatic Ductal Adenocarcinoma ... Metastatic Pancreatic Ductal Adenocarcinoma Phase 3
  • Country: 
    United States
  • Country: 
    Australia
  • Country: 
    Belgium
  • Country: 
An Open-Label, Single-arm Study to Evaluate the Safety and Efficacy of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutation-Positive Metastatic Non-Small Cell Lung Cancer Carcinoma, Non-Small-Cell Lung Phase 2
  • Country: 
    China